Disease relevance of Pharmacogenetics

• Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome [1].
• In addition, these findings have potentially important implications in the application of pharmacogenetics across a range of common diseases, including HIV, epilepsy and colorectal cancer [2].
• Recent advances in the pharmacogenetics of, for example, 6MP and 5FU will possibly enable researchers to identify patients who may have an increased risk of toxicity [3].
• Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer [4].
• The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis [5].

Psychiatry related information on Pharmacogenetics

• Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics [6].
• This review focuses on the current status and future directions of pharmacogenetics research into responses to treatments for nicotine dependence and smoking cessation [7].

High impact information on Pharmacogenetics

• This article reviews the molecular genetics and pharmacogenetics of opiate and cocaine addictions, focusing primarily on genes of the opioid and monoaminergic systems that have been associated with or have evidence for linkage to opiate or cocaine addiction [8].
• We review here recent ideas and findings regarding pharmacogenomics of components of the autonomic nervous system, in particular, neuronal nicotinic acetylcholine receptors, postsynaptic receptors with which the parasympathetic and sympathetic neurotransmitters, acetylcholine (ACh) and norepinephrine, respectively, interact [9].
• Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics [10].
• Pharmacogenetics of sulfotransferase [11].
• Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase [12].

Chemical compound and disease context of Pharmacogenetics

• Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease [13].
• Enhanced understanding of the pharmacogenetics of methylation may make it possible to understand and predict individual variation in the biotransformation, toxicity and therapeutic effect of compounds that undergo methyl conjugation [14].

Biological context of Pharmacogenetics

• Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments [8].
• TPMT genetic polymorphisms represent a striking example of the potential clinical value of pharmacogenetics [15].
• Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies [16].
• Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment [17].
• X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients [18].

Anatomical context of Pharmacogenetics

• Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity [19].
• Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells [20].

Associations of Pharmacogenetics with chemical compounds

• We analyzed the relationship between the pharmacogenetics of tolbutamide metabolism and the controversial University Group Diabetes Program (UGDP) study [21].
• Application of pharmacogenetics to optimization of mercaptopurine dosing [22].
• In silico pharmacogenetics of warfarin metabolism [23].
• These enzymes are polymorphic and have an important place in the history of pharmacogenetics, being first identified as responsible for the polymorphic inactivation of the anti-tubercular drug isoniazid [24].
• Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia [25].

Gene context of Pharmacogenetics

• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [26].
• In particular, the CYP3A4 and CYP3A5 genes play an especially important role in pharmacogenetics, since they metabolize >50% of the drugs on the market [27].
• We set out to study the pharmacogenetics of human arsenic methyltransferase (AS3MT, previously CYT19) [16].
• For this review, existing studies in ADHD pharmacogenomics were reviewed to assess current knowledge and provide a basis for planning future research [28].
• Human phenol sulfotransferase pharmacogenetics: STP1 gene cloning and structural characterization [29].

Analytical, diagnostic and therapeutic context of Pharmacogenetics

• Pharmacotherapy and pharmacogenetics of nicotine dependence [30].
• Although interest in ADHD pharmacogenomics is encouraging, preliminary studies have been limited by small sample sizes, inconsistent research designs, retrospective reports, and a focus on symptom response [28].
• Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis [31].
• The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model [32].
• Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics [33].

References